tiprankstipranks
Adhera Therapeutics (ATRX)
OTHER OTC:ATRX
US Market

Adhera Therapeutics (ATRX) Stock Price & Analysis

11 Followers

ATRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range<$0.01 - $0.60
Previous Close$0.01
Volume10.08K
Average Volume (3M)111.03K
Market Cap
$100.37K
Enterprise Value$10.63M
Total Cash (Recent Filing)$58.00K
Total Debt (Recent Filing)$10.59M
Price to Earnings (P/E)>-0.1
Beta1.69
May 18, 2018
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding7,220,900
10 Day Avg. Volume72,102
30 Day Avg. Volume111,027
Standard Deviation0.44
R-Squared0.00015
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-30.64
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-16.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ATRX FAQ

What was Adhera Therapeutics’s price range in the past 12 months?
Adhera Therapeutics lowest stock price was <$0.01 and its highest was $0.60 in the past 12 months.
    What is Adhera Therapeutics’s market cap?
    Currently, no data Available
    When is Adhera Therapeutics’s upcoming earnings report date?
    Adhera Therapeutics’s upcoming earnings report date is May 18, 2018 which is 2141 days ago.
      How were Adhera Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is Adhera Therapeutics overvalued?
      According to Wall Street analysts Adhera Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Adhera Therapeutics pay dividends?
        Adhera Therapeutics does not currently pay dividends.
        What is Adhera Therapeutics’s EPS estimate?
        Adhera Therapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Adhera Therapeutics have?
        Adhera Therapeutics has 7,220,900 shares outstanding.
          What happened to Adhera Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Adhera Therapeutics?
          Currently, no hedge funds are holding shares in ATRX
          ---

          Adhera Therapeutics Stock Smart Score

          N/A
          Not Ranked
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Negative
          20 days / 200 days
          Momentum
          -97.60%
          12-Months-Change

          Fundamentals

          Return on Equity
          Trailing 12-Months
          Asset Growth
          -82.78%
          Trailing 12-Months

          Company Description

          Adhera Therapeutics

          Adhera Therapeutics, Inc. engages in the discovery, development, and commercialization of drug therapeutics for hypertension. It offers Perstalia, which contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension. The company was founded on September 23, 1983 and is headquartered in Durham, NC.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          ADMA Biologics
          CymaBay Therapeutics
          Cyclacel Pharmaceuticals
          Medicinova
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis